New Drug Product: Imbruvica

Treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Women 70+: No Routine Mammograms

Mammogram breast cancer screenings for women aged ≥70 may cause more harm than good.

Antipsychotics for Glioblastoma

Researchers have discovered that FDA-approved antipsychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma.

Skin Cancer Self-Treatment Harmful

Home mole removal and skin cancer treatment is associated with poor cosmesis and negative outcomes.

Diabetes, Obesity, and Cancer

Diabetes and cancer coexist in the same patient more frequently than would be expected by chance, even adjusting for age and other factors.

Decrease in PSA Screenings

Prostate-specific antigen screening has decreased since publication of the U.S. Preventive Services Task Force Recommendations against screening.

Reducing Cancer Care Cost

Experts have identified three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients.

Genes and Prostate Cancer Relapse

A new study examined how a genetic mutation in untreated patients is linked to aggressive prostate cancer later in life.

News

Arzerra Gains New Indication

The FDA has approved a new indication for Arzerra (ofatumumab; GlaxoSmithKline) to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

Volasertib Designated Orphan Drug for Acute Myeloid Leukemia

The FDA has granted Orphan Drug designation to volasertib (Boehringer Ingelheim) for acute myeloid leukemia (AML).

AbbVie Launches Veliparib Trial for NSCLC

AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).

Rates of Interval Cancers in CRC Patients

Rates of Interval Cancers in CRC Patients

Six percent of patients with colorectal cancer (CRC) have interval cancers, which develop within six to 60 months of colonoscopy.

Streptococcus bovis and CRC: What's the Connection?

Presence of a particular biotype of the Streptococcus bovis bacterium can be an indicator of a GI malignancy.

Charts

Make prescribing decisions with our comparative charts and treatment algorithms.

Calculators

Quickly and accurately perform clinical calculations.

Patient Information Fact Sheets

Download or print easy-to-read disease leaflets for your patients.

Featured courses from mycme

Understanding Current and Emerging Therapies for Head and Neck CancersExternal web site

This activity can help oncology nurses refresh their knowledge of the risks and treatments for ...

CE 0.50 Credits

Vertebroplasty is effective for managing myelomatous VCFsExternal web site

Nurse awareness of this treatment option and the patient selection criteria may be a significant ...

CE 0.60 Credits

Case 5: A 63-Year-Old Female With Gastric AdenocarcinomaExternal web site

A 63-year-old Hispanic female, who presented with a syncopal episode while walking down the street, ...

CME 0.75 Credits
More myCME courses »

Sign Up for Free e-newsletters